Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.785
Neutral
RSI(14)
53.783
Neutral
STOCH(KDJ)(9,3,3)
53.869
Neutral
ATR(14)
2.075
High Vlolatility
CCI(14)
93.734
Neutral
Williams %R
41.374
Buy
TRIX(12,20)
0.303
Sell
StochRSI(14)
28.400
Sell
Uniqure NV
QURE25.650USD
+1.130+4.61%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.59BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Uniqure NV
Currency: USD Updated: 2026-02-06Key Insights
Uniqure NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 56 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Uniqure NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Uniqure NV Highlights
StrengthsRisks
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.12M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 27.12M.
Undervalued
The company’s latest PE is -5.83, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 59.36M shares, decreasing 3.95% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 254.08K shares of this stock.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
50.500
Target Price
+89.49%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Uniqure NV is 6.55, ranking 241 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 3.70M, representing a year-over-year increase of 61.83%, while its net profit experienced a year-over-year increase of 81.46%.
Score
Financials
7.45
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.85
Operational Efficiency
2.94
Growth Potential
8.26
Shareholder Returns
7.24
Uniqure NV's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Uniqure NV is 5.88, ranking 357 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.83, which is -89.05% below the recent high of -0.64 and -210.15% above the recent low of -18.09.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 56/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Uniqure NV is 8.29, ranking 137 out of 392 in the Biotechnology & Medical Research industry. The average price target is 53.00, with a high of 95.00 and a low of 30.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
50.500
Target Price
+89.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Uniqure NV
QURE
14
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Uniqure NV is 8.84, ranking 52 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 29.23 and the support level at 21.61, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
25.864
Sell
MA10
24.835
Buy
MA20
23.865
Buy
MA50
23.661
Buy
MA100
34.184
Sell
MA200
24.527
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Uniqure NV is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 95.29%, representing a quarter-over-quarter increase of 6.44%. The largest institutional shareholder is The Vanguard, holding a total of 1.04M shares, representing 1.67% of shares outstanding, with 3.12% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Uniqure NV is 2.28, ranking 240 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.64
VaR
+6.21%
240-Day Maximum Drawdown
+72.36%
240-Day Volatility
+187.15%
Return
Best Daily Return
60 days
+17.93%
120 days
+247.73%
5 years
+247.73%
Worst Daily Return
60 days
-10.75%
120 days
-49.34%
5 years
-49.34%
Sharpe Ratio
60 days
-0.00
120 days
+1.15
5 years
+0.43
Risk Assessment
Maximum Drawdown
240 days
+72.36%
3 years
+82.97%
5 years
+90.11%
Return-to-Drawdown Ratio
240 days
+1.71
3 years
+0.12
5 years
-0.05
Skewness
240 days
+12.00
3 years
+13.67
5 years
+15.77
Volatility
Realised Volatility
240 days
+187.15%
5 years
+111.40%
Standardised True Range
240 days
+8.17%
5 years
+4.49%
Downside Risk-Adjusted Return
120 days
+421.63%
240 days
+421.63%
Maximum Daily Upside Volatility
60 days
+89.21%
Maximum Daily Downside Volatility
60 days
+60.20%
Liquidity
Average Turnover Rate
60 days
+2.07%
120 days
+2.74%
5 years
--
Turnover Deviation
20 days
-48.92%
60 days
-30.06%
120 days
-7.55%
Peer Comparison
Biotechnology & Medical Research
Uniqure NV
QURE
7.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
